IMPLEMENTATION LEVEL

IFI

AFFECTED FLOW

Inflow

ANNOUNCED AS TEMPORARY

No

NON-TRADE-RELATED RATIONALE

No

ELIGIBLE FIRMS

firm-specific

JUMBO

No

TARIFF PEAK

No
← back to the state act
Inception date: 07 Jan 2019 | Removal date: open ended

State loan

The loan agreement between the European Investment Bank (EIB) and Novozymes A/S was signed on 7 January 2019 and has a total value of EUR 100 million (approx. USD 114.7 million).

The loan will support the company's RDI project concerning the development of certain biological solutions, microorganisms and industrial enzymes. More specifically, the EIB stated: "The RDI activities will focus on the development of products and solutions that enhance product quality and process/energy efficiency in industries such as detergents, food and beverages, bioenergy, agriculture and feed and technical industries."

Novozymes A/S has its headquarters in Denmark and is a producer of microorganisms and industrial enzymes. The company holds a 48% market share in industrial enzymes and sells its products to 130 countries around the world.

A state act in the GTA database is assessed solely in terms of the extent to which its implementation affects foreign commercial interests. On this metric, the investment support granted here is discriminatory.

AFFECTED COUNTRIES

MAP
TABLE
EXPORT

AFFECTED SECTORS AND PRODUCTS

341 Basic organic chemicals
3507 Enzymes; prepared enzymes not elsewhere specified or included.
350710 Rennet and concentrates thereof
350790 Other
352 Pharmaceutical products
3002 Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micr
300290 Other

Please report this page in case you detect an inaccuracy in its content.